News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Neurobo Pharmaceuticals Receives First Site IRB Approval for a Phase 2a Clinical Trial Evaluating DA-1241 as a Potential Treatment for NASH
Friday, August 04, 2023NeuroBo Pharmaceuticals Inc Nasdaq NRBO a biotechnology company in the clinicalstage is dedicated to addressing cardiometabolic diseases
IGC Pharma Extends Phase 2 Trial of IGC-AD1 to Include Collaboration with the University of Puerto Rico
Thursday, August 03, 2023IGC Pharma Inc NYSE American IGC announced the addition of a trial site at the University of Puerto Rico network to expand its ongoing Phase clinical trial investigating IGCAD the companys lead drug asset
Cybin Commences Dosing of Last Cohort in Phase 2 Trial of CYB003 for Major Depressive Disorder
Thursday, August 03, 2023Cybin Inc NYSE American CYBN NEO CYBN is making significant strides in its commitment to revolutionize mental healthcare through the development of innovative psychedelicbased treatment options
Cadrenal Therapeutics Expands the Scope of Tecarfarin to Incorporate Patients With Implanted Medical Devices for Heart Diseases
Wednesday, August 02, 2023Cadrenal Therapeutics Inc Nasdaq CVKD a biopharmaceutical company has recently announced its plan to expand the focus of its latestage novel oral anticoagulant tecarfarin
Entrada Therapeutics Receives Green Light for Phase 1 Clinical Trial of ENTR-601-44 in the UK to Explore Treatment Potential for Duchenne Muscular Dystrophy
Wednesday, August 02, 2023Entrada Therapeutics Inc Nasdaq TRDA is a biopharmaceutical company with a mission to revolutionize patient lives by introducing intracellular Endosomal Escape Vehicle EEVtherapeutics as a new category of medicines
Replimune and Incyte Announce Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Cutaneous Squamous Cell Carcinoma Patients
Tuesday, August 01, 2023Replimune Group Inc NASDAQ REPL and Incyte NASDAQ INCY have jointly announced a clinical trial collaboration and supply agreement
Ultragenyx Initiates Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial for UX701 Gene Therapy in Wilson Disease Treatment
Tuesday, August 01, 2023Ultragenyx Pharmaceutical Inc NASDAQ RARE recently announced the initiation of the second doseescalation cohort in its pivotal Phase Cyprus study after completing dosing and safety review in the first cohort
Biohaven's Taldefgrobep Alfa Granted EU Orphan Drug Designation for Spinal Muscular Atrophy
Tuesday, August 01, 2023Biohaven Ltd NYSE BHVN has recently obtained orphan medicinal product designation from the European Commission EC for taldefgrobep alfa a novel antimyostatin adnectin aimed at treating spinal muscular atrophy SMA
Marinus Pharmaceuticals Receives European Commission Approval for ZTALMY® (Ganaxolone) as Adjunctive Therapy for Epileptic Seizures Associated With CDKL5 Deficiency Disorder
Monday, July 31, 2023Marinus Pharmaceuticals Inc Nasdaq MRNS has received approval from the European Commission EC for the oral suspension medication ZTALMY ganaxolone
Ionis Completes Enrollment in Pivotal Phase 3 CARDIO-TTRansform Trial for Patients With TTR-mediated Amyloid Cardiomyopathy
Monday, July 31, 2023Ionis Pharmaceuticals Inc Nasdaq IONS has successfully completed the enrollment phase of the Phase CARDIOTTRansform cardiovascular outcomes study for eplontersen an investigational drug targeting transthyretinmediated amyloid cardiomyopathy ATTRCM
